Peptide And Oligonucleotide CDMO Market Set To Grow From $2.7 Billion In 2026 To $4.02 Billion By 2030 At A CAGR Of 10.5%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Peptide And Oligonucleotide CDMO Market Growth From $2.7 Billion In 2026 To $4.02 Billion By 2030 At A CAGR Of 10.5%
The market for peptide and oligonucleotide CDMO services has experienced significant expansion in recent years, with projections indicating growth from $2.42 billion in 2025 to $2.7 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.9%. This historical uptick is largely driven by several factors, including the rise of peptide-based therapeutics, the growing intricacy of synthetic oligonucleotides, constrained in-house production capacities among drug developers, heightened regulatory compliance demands, and the early-stage adoption of antisense and peptide-based drugs.
The market size for peptide and oligonucleotide CDMOs is projected to experience substantial expansion over the coming years. By 2030, it is set to reach $4.03 billion, reflecting a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period is driven by factors such as the broadening of oligonucleotide therapeutic pipelines, heightened investment in treatments for rare diseases and oncology, an increasing need for swift production of clinical trial materials, a growing preference for partnerships with specialized CDMOs, and enhancements in solid-phase synthesis technologies. Key emerging trends expected in this period include the growing tendency to outsource the manufacturing of peptides and oligonucleotides, rising demand for cGMP-compliant production of complex molecules, the broadening of comprehensive development and manufacturing service offerings, a strengthened focus on high-potency and high-purity therapeutic options, and a greater uptake of scalable and flexible manufacturing systems.
Download A Free Sample Report For Comprehensive Market Insights:
Peptide And Oligonucleotide CDMO Market Growth Factors Supporting Long-Term Expansion
The increasing uptake of personalized medicine is set to drive expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine is a healthcare strategy that customizes medical decisions and therapies based on individual traits like genetics, environment, and lifestyle. This trend is gaining momentum due to factors such as progress in genomic technologies, deeper insights into disease mechanisms at the molecular level, and a rising need for more effective, targeted treatments aligned with patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital to this approach, as they produce custom therapeutic peptides and oligonucleotides designed for specific patient needs. For example, in February 2024, the Personalized Medicine Coalition, a UK-based group advocating for personalized medicine, reported that the FDA’s Center for Drug Evaluation and Research (CDER) approved 16 new personalized therapies for rare disease patients, compared to 6 in 2022. Consequently, the growing embrace of personalized medicine is fueling the growth of the peptide and oligonucleotide CDMO market.
Peptide And Oligonucleotide CDMO Market Segment Landscape: Which Areas Lead Market Development?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
Peptide And Oligonucleotide CDMO Market Industry Trends Shaping Future Revenue Growth
Key players in the peptide and oligonucleotide CDMO space are increasingly emphasizing strategic collaborations to broaden their service portfolios, strengthen their technological expertise, and extend their market presence. Such alliances for peptide development and production involve formal agreements between two entities committed to the creation and manufacturing of peptide-based drugs. A notable example occurred in May 2023, when PolyPeptide Group AG—a contract development and manufacturing organization based in the US—formed a partnership with Germany’s biotechnology firm Numaferm GmbH, specifically targeting peptide development and manufacturing. This collaboration is designed to leverage PolyPeptide’s cGMP manufacturing infrastructure and market reach, alongside Numaferm’s specialized knowledge in sustainable peptide production and biochemical platforms. Together, they aim to investigate the development of promising peptide candidates, with a focus on achieving more environmentally friendly production of active pharmaceutical ingredients.
Peptide And Oligonucleotide CDMO Market Industry Leaders And Market Competition
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Access The Complete Peptide And Oligonucleotide CDMO Market Report:
Peptide And Oligonucleotide CDMO Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
